Therapeutic Advances in Phage-Derived Antimicrobial Enzymes

Abstract

The emergence of multidrug-resistant (MDR) bacterial infections presents a significant challenge to contemporary medicine, necessitating the exploration of novel therapeutic strategies beyond conventional antibiotics. Phage-derived antimicrobial enzymes, particularly endolysins and depolymerases, have garnered attention due to their unique mechanisms of action, specificity, and efficacy against resistant pathogens. This review synthesizes current evidence regarding the clinical potential, mechanisms, and developments in phage-derived enzymes as therapeutic agents, emphasizing recent advances, clinical applications, and guideline perspectives for healthcare professionals

Introduction

Antibiotic resistance continues to escalate globally, undermining the efficacy of traditional antimicrobial treatments and contributing to increased morbidity, mortality, and healthcare costs. Bacteriophage-derived enzymes, including endolysins and depolymerases, represent a promising class of antimicrobials with the capacity to lyse pathogenic bacteria, disrupt biofilms, and offer selective bactericidal activity. Their clinical translation is accelerating, propelled by advances in molecular biology, bioengineering, and regulatory frameworks. This review provides a comprehensive synthesis of the role, mechanisms, and clinical relevance of phage-derived antimicrobial enzymes in contemporary infectious disease management.

Epidemiology / Disease Burden

Antimicrobial resistance (AMR) is a pressing global health crisis, with the World Health Organization (WHO) estimating at least 700,000 deaths annually attributable to resistant infections, a figure projected to rise dramatically if unchecked. Gram-positive and Gram-negative pathogens such as Staphylococcus aureus, Pseudomonas aeruginosa, and Acinetobacter baumannii are particularly problematic in healthcare-associated infections, where traditional antibiotics often fail. The economic and clinical burden includes prolonged hospitalizations, increased need for intensive care, and higher mortality rates. These trends have intensified the search for alternative therapies, positioning phage-derived enzymes as a focal point of translational research and clinical innovation.

Pathophysiology

Bacteriophages, or phages, are viruses that infect bacteria and naturally produce enzymes most notably endolysins and depolymerases to degrade bacterial cell walls and extracellular matrices during their replication cycle. Endolysins are peptidoglycan hydrolases that cleave specific bonds within the bacterial cell wall, leading to rapid osmotic lysis. Depolymerases target polysaccharide capsules and biofilms, enhancing phage infectivity and exposing bacteria to immune clearance. These enzymes act externally when purified and administered directly, bypassing conventional resistance mechanisms such as efflux pumps and target modifications, and exerting potent lytic activity even against dormant or biofilm-embedded bacteria.

Risk Factors

Patients most at risk for infections amenable to phage-derived enzyme therapy include those with chronic wounds, burns, cystic fibrosis, immunosuppression, or implanted medical devices populations prone to persistent, biofilm-associated, or MDR bacterial infections. Hospitalized patients, particularly in intensive care or post-surgical settings, represent a key demographic due to frequent invasive procedures and high antibiotic exposure. Additionally, individuals with genetic defects impairing innate immunity may benefit from the specificity and rapid action of these novel antimicrobials.

Clinical Features

Infections targeted by phage-derived enzymes often present with signs of localized or systemic inflammation, delayed wound healing, persistent drainage, or device-associated sepsis. Biofilm-associated infections are particularly recalcitrant, exhibiting chronicity, inadequate response to antibiotics, and high rates of recurrence. Characteristic features may include non-resolving pneumonia, osteomyelitis, prosthetic joint infection, or chronic otitis media. The ability of phage enzymes to penetrate biofilms and lyse encapsulated bacteria addresses a critical unmet clinical need in these settings.

Diagnosis

Rapid and accurate identification of causative pathogens is essential for effective use of phage-derived enzymes. Diagnostic modalities include culture-based methods, molecular diagnostics (e.g., PCR, next-generation sequencing), and susceptibility assays tailored to phage enzyme activity. Recent advances in point-of-care diagnostics and biomarker discovery enable precise pathogen identification and monitoring of therapeutic response, facilitating personalized antimicrobial strategies. Additionally, the characterization of bacterial capsule types and biofilm matrices informs the selection of specific depolymerases or endolysins for targeted therapy.

Treatment & Management

Phage-derived antimicrobial enzymes are administered as purified proteins, locally or systemically, depending on infection site and severity. Their safety profile is favorable, with limited immunogenicity and minimal disruption to commensal microbiota. In clinical trials and compassionate use cases, endolysins have demonstrated efficacy against Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), while engineered enzymes and combination therapies expand their spectrum to Gram-negative organisms. Adjunctive use with antibiotics or as part of phage cocktails enhances synergistic effects and reduces the risk of resistance. Optimal dosing, route of administration, and pharmacokinetics are under active investigation to inform clinical practice.

Recent Advances / Emerging Therapies

Recent innovations include the development of engineered endolysins with enhanced thermostability, broader spectrum, and improved pharmacodynamics. Modular design allows fusion of cell wall-binding domains and lytic enzymes, increasing potency against resistant strains. Recombinant depolymerases facilitate biofilm disruption and immune system access, showing promise in device-associated and respiratory infections. Clinical trials, such as those evaluating exebacase (CF-301) and other lysins, report favorable safety and efficacy outcomes, with rapid bacterial clearance and improved clinical endpoints. Regulatory pathways for biologic antimicrobials are evolving, with agencies recognizing the urgent need for novel modalities. Ongoing research explores combination approaches, enzyme encapsulation, and targeted delivery systems to maximize therapeutic benefit and minimize off-target effects.

Guideline Recommendations

While formal guidelines for phage-derived enzyme therapeutics are evolving, consensus statements from infectious disease societies emphasize their potential role as adjuncts or alternatives in MDR and biofilm-associated infections. Key recommendations highlight the necessity of pathogen-specific diagnostics, individualized therapy, and monitoring for resistance emergence. Integration into antimicrobial stewardship programs and multidisciplinary care models is encouraged. As further clinical data emerge, formal incorporation into evidence-based guidelines is anticipated, particularly for indications with limited treatment options.

Conclusion

Phage-derived antimicrobial enzymes represent a paradigm shift in the management of resistant bacterial infections, offering targeted, potent, and innovative solutions to a mounting global crisis. Ongoing research, clinical trials, and translational advances are paving the way for their integration into routine medical practice. Continued collaboration among clinicians, researchers, and regulatory bodies is essential to realize the full therapeutic potential of these biologic agents and to address the urgent needs of patients affected by MDR and biofilm-associated infections.